Skip to main content
Smart Investors Daily
NU

NYSE · NUVB

Nuvation Bio Inc.

Healthcare · Biotechnology

$4.95

Down-$0.07 (-1.41%)

Updated Oct 6, 2026, 9:50 PM

SID Score

4.9/10

Composite research score

Smart Money

58/100

Neutral

Market cap
2.83B
P/E ratio
-13.02
Dividend yield
0.00%
52-week range
$4.05 – $7.58
Volume
9.97M
Avg. volume
8.66M

Price performance · NUVB

NUVB price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

NUVB closed at $4.95 after 20 trading sessions, down 25.11% for the selected period.

Last close
$4.95
Period change
-25.11%
Period low
$4.95
Period high
$6.61
Daily close
View OHLC price history
NUVB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$5.12$5.16$4.85$4.959.97M
Oct 2, 2026$5.66$5.66$5.03$5.1414.83M
Oct 1, 2026$5.57$5.616$5.452$5.563.47M
Sep 30, 2026$5.81$5.825$5.59$5.605.55M
Sep 29, 2026$5.59$5.69$5.54$5.623.07M
Sep 28, 2026$5.68$5.68$5.48$5.604.59M
Sep 25, 2026$5.73$5.825$5.67$5.742.82M
Sep 24, 2026$5.69$5.78$5.535$5.735.71M
Sep 23, 2026$6.07$6.07$5.69$5.714.61M
Sep 22, 2026$6.26$6.26$5.955$6.104.32M
Sep 21, 2026$6.00$6.105$5.8596$6.073.03M
Sep 18, 2026$6.15$6.18$5.82$5.854.43M
Sep 17, 2026$5.96$6.16$5.92$6.075.74M
Sep 16, 2026$5.80$5.82$5.655$5.782.78M
Sep 15, 2026$5.90$5.91$5.63$5.807.05M
Sep 14, 2026$5.90$6.135$5.77$5.9410.03M
Sep 11, 2026$6.36$6.39$5.95$6.074.32M
Sep 10, 2026$6.44$6.45$6.17$6.287.98M
Sep 9, 2026$6.55$6.715$6.50$6.522.61M
Sep 8, 2026$6.69$6.746$6.58$6.612.54M

Latest NUVB news

The latest Smart Investors Daily articles mentioning NUVB.

NUVB research

Overview

Company profile and research snapshot.

Company profile

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$13.00
Implied upside
—
Analysts
—
NUVB recent ratings
DateFirmRatingTarget
Sep 30, 2026CitigroupBuy—
Sep 16, 2026CitizensMarket Outperform—
Sep 16, 2026WedbushOutperform—
Aug 21, 2026Cantor FitzgeraldOverweight—
Aug 18, 2026JP MorganOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 3, 2026

Top Penny Stocks To Own In October 2026

Spiking Treasury yields have pushed many investors back toward safer assets, which has punished weaker balance sheets and rewarded stronger ones. That creates an opening for you. Solid, low priced companies that already showed gains over the past year and still look cheap on fundamental metrics suddenly look more interesting. This article examines three such penny stocks that combine financial resilience with positive analyst growth forecasts. The three elite penny stocks in this article are...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.